• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Updated rationale for the initial antipsychotic selection for patients with schizophrenia.

作者信息

Markota Matej, Morgan Robert J, Leung Jonathan G

机构信息

Department of Psychiatry & Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.

Department of Pharmacy, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.

出版信息

Schizophrenia (Heidelb). 2024 Sep 2;10(1):74. doi: 10.1038/s41537-024-00492-y.

DOI:10.1038/s41537-024-00492-y
PMID:39223138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11369117/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e278/11369117/449f4e965d18/41537_2024_492_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e278/11369117/449f4e965d18/41537_2024_492_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e278/11369117/449f4e965d18/41537_2024_492_Fig1_HTML.jpg

相似文献

1
Updated rationale for the initial antipsychotic selection for patients with schizophrenia.精神分裂症患者初始抗精神病药物选择的更新依据。
Schizophrenia (Heidelb). 2024 Sep 2;10(1):74. doi: 10.1038/s41537-024-00492-y.
2
Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms.抗精神病药物治疗精神分裂症维持期：指南和算法的更新系统评价。
Schizophr Res. 2020 Jan;215:8-16. doi: 10.1016/j.schres.2019.09.013. Epub 2019 Nov 26.
3
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design.首发精神分裂症患者中比较抗精神病药物治疗的序贯多项适应性随机试验（SMART-CAT）：原理与试验设计。
Schizophr Res. 2021 Apr;230:87-94. doi: 10.1016/j.schres.2020.11.010. Epub 2020 Dec 2.
4
Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.精神分裂症患者早期无反应的治疗：评估抗精神病药物剂量增加的疗效。
BMC Psychiatry. 2015 Oct 31;15:271. doi: 10.1186/s12888-015-0629-0.
5
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.临床抗精神病药物干预有效性试验（CATIE）项目精神分裂症试验中的神经认知评估：开发、方法及原理
Schizophr Bull. 2003;29(1):45-55. doi: 10.1093/oxfordjournals.schbul.a006990.
6
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.非典型抗精神病药物作为精神分裂症的一线治疗：理论依据与假说。
J Clin Psychiatry. 1996;57 Suppl 11:68-71.
7
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
8
Increasing antipsychotic dose for non response in schizophrenia.增加抗精神病药物剂量以应对精神分裂症无反应情况。
Cochrane Database Syst Rev. 2018 May 11;5(5):CD011883. doi: 10.1002/14651858.CD011883.pub2.
9
An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia.对影响精神分裂症患者初始抗精神病药物治疗依从性的因素的研究。
Curr Med Res Opin. 2007 Jan;23(1):97-104. doi: 10.1185/030079907X162665.
10
Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.帕利哌酮棕榈酸酯疗效研究（PRIDE）的设计和原理：一项新的比较试验，比较每月一次的帕利哌酮棕榈酸酯与每日口服抗精神病药物治疗，以延迟精神分裂症患者的治疗失败时间。
J Clin Psychiatry. 2014 Dec;75(12):1388-93. doi: 10.4088/JCP.13m08965.

本文引用的文献

1
A systematic review of clozapine-associated inflammation and related monitoring.氯氮平相关炎症及相关监测的系统评价
Pharmacotherapy. 2023 Dec;43(12):1364-1396. doi: 10.1002/phar.2887. Epub 2023 Oct 31.
2
A case series of clozapine titrations affected by inflammatory processes.受炎症过程影响的氯氮平滴定病例系列。
Schizophr Res. 2024 Jun;268:94-97. doi: 10.1016/j.schres.2023.08.007. Epub 2023 Aug 24.
3
Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.
抗精神病药物对初发急性精神分裂症成年患者的长期疗效：系统评价与网状Meta分析
World Psychiatry. 2023 Jun;22(2):315-324. doi: 10.1002/wps.21089.
4
Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.抗精神病药物中长期治疗期间精神分裂症患者的代谢副作用：随机对照试验的网状荟萃分析
World Psychiatry. 2023 Feb;22(1):116-128. doi: 10.1002/wps.21036.
5
The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis.精神分裂症亚组患者对不同抗精神病药物的反应：系统评价和荟萃分析。
Lancet Psychiatry. 2022 Nov;9(11):884-893. doi: 10.1016/S2215-0366(22)00304-2. Epub 2022 Oct 10.
6
Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia.鲁拉西酮、布瑞哌唑和卡立哌嗪治疗精神分裂症的系统文献综述与网状Meta分析
Int Clin Psychopharmacol. 2023 Jan 1;38(1):45-56. doi: 10.1097/YIC.0000000000000427. Epub 2022 Jul 22.
7
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.早期非改善型精神分裂症患者换用氨磺必利或奥氮平的随机、双盲试验。
Schizophr Bull. 2022 Nov 18;48(6):1273-1283. doi: 10.1093/schbul/sbac068.
8
Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.精神分裂症患者的死亡率：相对风险以及加重或减轻因素的系统评价和荟萃分析
World Psychiatry. 2022 Jun;21(2):248-271. doi: 10.1002/wps.20994.
9
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.抗精神病药引起的体重增加：随机对照试验的剂量反应荟萃分析。
Schizophr Bull. 2022 May 7;48(3):643-654. doi: 10.1093/schbul/sbac001.
10
An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.基于六祖禅法的个体化剂量滴定、CRP 和氯氮平水平来提高氯氮平滴定安全性的国际成人指南
Pharmacopsychiatry. 2022 Mar;55(2):73-86. doi: 10.1055/a-1625-6388. Epub 2021 Dec 15.